- Home
- PBA vs DGX Comparison
PBA vs DGX Comparison
Compare PBA & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBA | DGX |
|---|---|---|
| Founded | 1997 | 1967 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3B | 23.2B |
| IPO Year | 2012 | 1996 |
Fundamental Metrics
Financial Performance| Metric | PBA | DGX |
|---|---|---|
| Price | $47.98 | $242.59 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 13 |
| Target Price | $60.00 | ★ $214.38 |
| AVG Volume (30 Days) | ★ 778.0K | 760.7K |
| Earning Date | 05-07-2026 | 04-21-2026 |
| Dividend Yield | ★ 4.58% | 1.82% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | N/A | ★ 5.08 |
| Revenue | N/A | ★ $11,035,000,000.00 |
| Revenue This Year | $3.45 | $7.53 |
| Revenue Next Year | $9.15 | $3.77 |
| P/E Ratio | ★ $21.43 | $48.15 |
| Revenue Growth | N/A | ★ 11.78 |
| 52 Week Low | $36.20 | $171.18 |
| 52 Week High | $51.58 | $247.19 |
Technical Indicators
Market Signals| Indicator | PBA | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 70.77 |
| Support Level | $46.77 | $191.82 |
| Resistance Level | $49.82 | N/A |
| Average True Range (ATR) | 0.78 | 4.40 |
| MACD | -0.04 | -0.39 |
| Stochastic Oscillator | 36.91 | 77.80 |
Price Performance
Historical ComparisonAbout PBA Pembina Pipeline Corp. (Canada)
Pembina Pipeline is a midstream company serving the Canadian and North American (primarily Bakken) markets with an integrated product portfolio. Its operations include transmission pipelines, oil and gas gathering, fractionation, storage, and natural gas liquid exports. It also has a joint venture through the Cedar LNG export terminal.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.